

ISV 2026 Pre-Congress Satellite Workshop

October 11, 2026

Antwerp

From Outbreak to Readiness

Special Workshop 1: 11:00 to 13:00

Organized by Eva Therapeutics, USA

AI HI 4 LMIC	
Artificial Intelligence informed by Human intelligence for Low- and Middle-Income Countries	
11:00 AM:	Welcome Jeff T Safrit CEO, EVA Therapeutics. • EVA Therapeutics Mission and Vision
11: 10 AM:	Computational Vaccinology at EVA Tx Annie De Groot, EVA Therapeutics • AI/Hi Tools for Vaccine Design used by EVA Tx • Current Equitable Vaccine Access Projects at EVA Tx
11: 25 AM:	VennVax Mpox Vaccine Progress Hapiloe Maranyane-Tshililo, AfriGen • Development of an mRNA Mpox vaccine in Capetown, South Africa
11: 40 AM:	Universal Influenza Vaccine “UTIV” Dan Hoft, Saint Louis University • Development of a cross-conserved, universal T cell epitope-driven vaccine for influenza
11: 55 AM:	Questions / Closing Remarks Jeff Safrit, Annie De Groot
Noon to 13:00 Lunch - sponsored by Eva Therapeutics	

Special Workshop 2: 13:00 to 18:00

**Co-Organized by the National Research Council Canada, and
International Vaccines Institute, South Korea**

Vaccine Manufacturing & Global Preparedness in the context of the current Ebola BDBV outbreak

Session I (13:00 to 13:50) – Current Status of Outbreak

Session Chair, Manon Cox, President of ISV

Time	Subject	Presenter
13:00 – 13:10	Welcome, Opening Remarks and Workshop Objectives	• Dr Manon Cox (President of ISV) • Dr Lakshmi Krishnan (Vice President, Life Sciences, NRC) • Dr In-Kyu Yoon (Deputy Director General, Integrated Development and Pandemic Readiness, IVI)
13:10 – 13:30	Keynote Speaker Ebola Bundibugyo outbreak – current status	Dr. Yazdan Yazdanpanah, Director, ANRS Emerging Infectious Diseases, France
13:30 – 13:50	Responding to Bundibugyo: 100 days into the Ebola epidemic, CEPI's perspective	Dr Katrin Ramsauer Program Lead/Deputy technical lead Bundibugyo response CEPI

Session II (14:00 – 15:00 hr): Current Outbreak on the ground Response

Session Chair – Dr. Margaret Liu (ISV Board Member)

Time	Subject	Presenter
14:00 – 14:20	African R&D and Manufacturing Readiness	Dr Nicaise Ndembe (Confirmed)

		Deputy Director General, IVI Africa Regional Office
14:20 – 14:40	DRC speaker (Title TBD)	Dr. Wessam Mankoula, African CDC Regional Director for Northern Africa at the RCC, Acting Head of Emergency Preparedness and Response
Session III: Bio-Medical Countermeasures Preparedness <i>Session Chair: Dr. Lakshmi Krishnan (ISV Board Member)</i>		
Time	Subject	Presenter
14:45-15:00	Canada's Biomedical Countermeasures Initiative – BDBV responsiveness	Rhonda KuoLee Executive Director, BioMedical Countermeasures Program, National Research council Canada
15:00-15:15	rVSV-EBOV vaccination protects ferrets from lethal Bundibugyo virus disease"	Dr. Logan Banadyga, Scientist, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada Secondary Affiliation: Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
15:15-15:30	From Bundibugyo to Disease X: Readiness for the Next Outbreak	Dr. In-Kyu Yoon, Deputy Director General, International Vaccines Institute, South Korea
BREAK 15:30– 15:40		
Session IV (15:30 – 16: 30): BDBV Vaccine Approaches <i>Session Chair, Dr. In-Kyu Yoon, IVI</i>		
15:40-16:00	From Cross-Reactivity to Protection: Opportunities and Challenges in BDBV Vaccine Development	Dr. Wim Adriaensen, Associate Professor Clinical Immunology Unit, Department of Clinical

		Sciences, Institute of Tropical Medicine, Antwerp, Belgium
16:00-16:20	mRNA platform: BDBV vaccine candidate	Dr. Hamilton Bennett, Executive Director, Resilience and R&D and Partnerships Moderna (
16:20-16:40	ChAdOx platform: Crisis to preparedness, vaccine development during and between outbreaks	Prof. Teresa Lambe, Vaccines and Immunology, University of Oxford
Session V (16:45–17:30): Vaccine Manufacturing, & Regional Efforts <i>Session Chair: Dr. Amine Kamen (McGill University, Canada)</i>		
Time	Subject	Presenter
16:45: 17:00	Adapting rVSV vaccine manufacturing for rapid outbreak responses.	Ali Aloueche Vice President, Business Development & Alliance Management, Hilleman Laboratories, Singapore
17:00-17:15	Bharat Biotech – Manufacturing and vaccine responsiveness (title TBD)	Badri Narayan Patnaik Director of Clinical Development, Bharat Biotech, India
17:15-17:30	CanSino Biologics - Ad5-EBOV to Ad5-BDBV: platform conversion and biomanufacturing readiness for filovirus outbreak preparedness	Chunlin Xin Vice President, External R&D and Scientific Affairs CanSino Biologics Inc., China
17:30- 17:45	African manufacturing perspective	Michael Lusiola (Regional Manufacturing Collaborative)
17:45-18:00	Closing Remarks	NRC and IVI Dr. Lakshmi Krishnan (NRC) & In-Kyu Yoon (IVI)